Patients Planning, not panic, as BIO weighs in on US vaccination woes At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
Market Access Makary: Drugs don’t have to take 10 years to get to market FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply held assumptions”.
News Amid staff cuts, FDA looks to AI to 'optimise' reviews The FDA has rolled out its highly-touted generative AI tool, almost a month early, with a promise to reduce the time taken for regulatory reviews.
News FDA announces generative AI pilot and rapid rollout plans The FDA has completed a pilot of a new GenAI technology for speeding up drug reviews– And it wants to move from pilot to implementation in two months
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face